SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Costantino who wrote ()12/9/1999 11:43:00 AM
From: FreedomForAll  Read Replies (1) of 4342
 
Paracelsian and Draco Natural Products Sign BioFIT Letter of
Intent

ITHACA, N.Y., Dec. 9 /PRNewswire/ -- Paracelsian, Inc. (OTC Bulletin Board: PRLN - news) paracelsian.com and Draco
Natural Products, Inc., San Jose, CA announced today that they have signed a Letter of Intent aimed at implementing the use of
Paracelsian's BioFIT© ``functional' quality assurance program in conjunction with the development, marketing and sale of Draco's line of
herbal products. The Letter of Intent calls for the completion of a formal Agreement within 90 days.

Draco Natural Products is the worldwide technology leader in the manufacture and raw material supply of Full Spectrum Standardized
Herbal Extracts(TM). Draco extracts are standardized to recognized markers, but provide the full range of plant constituents in the correctly
balanced proportions that nature intended. The products are solvent and carrier free, and produced in GMP, ISO9000 certified facilities.
Draco is a major supplier to many of the largest and most respected dietary supplement manufacturers. Their constituency of customers
spans all areas of the industry, including Natural Products, Multi-level Marketing and Food, Drug and Mass Market.

The BioFIT© ``functional' quality assurance program (U.S. Patent Pending) provides a unique way to validate the label claims of herbal
products by guaranteeing biological activity, in mechanisms associated with the product's benefit claim, that is equal to or better than that
seen with a clinically tested reference product. Since, in the case of herbal products, chemical analysis alone has proven to be an inadequate
predictor of biological activity, BioFIT© offers consumers a new, better way to differentiate from among the countless product offerings
available to them.

``We are looking forward to having Draco Natural Products become the first BioFIT© certified raw material supplier,' said Bernie Landes,
Paracelsian's President and CEO. ``Not only does it reflect Draco's desire and ability to distinguish its superior quality herbal products from
lower quality competitive products, it also represents the dawning of a new era of quality assurance for herbal products in which consumers
will be able to easily determine which of the myriad of products on the shelf can back up their label claims,' he added. ``We now look
forward to a rapid proliferation of BioFIT© Certified products throughout the dietary supplement market, with those made from Draco's
BioFIT© Certified Bioactive (TM) raw materials leading the way,' he concluded.

``Because Draco's Full Spectrum Standardized Herbal Extracts(TM) have a proven track record of high levels of activity, our products are
ripe for a program such as Paracelsian's BioFIT,' said Jerry Wu, CEO of Draco Natural Products. ``We already meet or exceed world class
standards for manufacturing quality and analyzed content levels, but we also want to show customers and consumers that they can count
on our products to be biologically functional,' he added.

Paracelsian is a unique biotechnology company with two primary areas of focus. Paracelsian develops functional bioassays. These assays
are the basis of its BioFIT(TM) Quality Assurance program for herbs, botanicals and other dietary supplements and the basis of products
used to monitor environmental toxins and to identify carcinogens. In addition, Paracelsian's Internet business leverages extensive
relationships in China and expertise in nutritional science to provide unique content and a variety of research services.

Notice: This news release may contain forward-looking statements. Investors are cautioned that such forward-looking statements involve
risks and uncertainties, including but not limited to, the results of research and development efforts, the effect of regulation by the United
States Food and Drug Administration and other agencies, the impact of competitive products, product development, commercialization and
technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext